Antibody-drug Conjugates in Breast Cancer: Advances and Prospects

Overview

Journal Cancer Biol Med

Specialty Oncology

Date 2025 Feb 17

PMID 39960255

Authors

Zhiqiang Shi

Yongjin Lu

Qiuchen Zhao

Yongsheng Wang

Pengfei Qiu

Affiliations

Soon will be listed here.

References

Emens L, Esteva F, Beresford M, Saura C, De Laurentiis M, Kim S . Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020; 21(10):1283-1295. DOI: 10.1016/S1470-2045(20)30465-4. View

Hurvitz S, Martin M, Jung K, Huang C, Harbeck N, Valero V . Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. J Clin Oncol. 2019; 37(25):2206-2216. PMC: 6774816. DOI: 10.1200/JCO.19.00882. View

Sung M, Tan X, Lu B, Golas J, Hosselet C, Wang F . Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1). Mol Cancer Ther. 2017; 17(1):243-253. DOI: 10.1158/1535-7163.MCT-17-0403. View

Coates J, Sun S, Leshchiner I, Thimmiah N, Martin E, McLoughlin D . Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. Cancer Discov. 2021; 11(10):2436-2445. PMC: 8495771. DOI: 10.1158/2159-8290.CD-21-0702. View

Alves F, Gil L, Vasconcelos de Matos L, Baleiras A, Vasques C, Neves M . Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer. Cureus. 2022; 14(2):e22330. PMC: 8938239. DOI: 10.7759/cureus.22330. View

Spring L, Tolaney S, Fell G, Bossuyt V, Abelman R, Wu B . Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. Ann Oncol. 2023; 35(3):293-301. DOI: 10.1016/j.annonc.2023.11.018. View

Joubert N, Beck A, Dumontet C, Denevault-Sabourin C . Antibody-Drug Conjugates: The Last Decade. Pharmaceuticals (Basel). 2020; 13(9). PMC: 7558467. DOI: 10.3390/ph13090245. View

Lopez-Miranda E, Perez-Garcia J, Di Cosimo S, Brain E, Ravnik M, Escriva-de-Romani S . Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. Cancers (Basel). 2020; 12(12). PMC: 7760511. DOI: 10.3390/cancers12123509. View

Bardia A, Hu X, Dent R, Yonemori K, Barrios C, OShaughnessy J . Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N Engl J Med. 2024; 391(22):2110-2122. DOI: 10.1056/NEJMoa2407086. View

10.

Harbeck N, Ciruelos E, Jerusalem G, Muller V, Niikura N, Viale G . Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nat Med. 2024; 30(12):3717-3727. PMC: 11645283. DOI: 10.1038/s41591-024-03261-7. View

11.

Bon G, Pizzuti L, Laquintana V, Loria R, Porru M, Marchio C . Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. J Exp Clin Cancer Res. 2020; 39(1):279. PMC: 7731769. DOI: 10.1186/s13046-020-01797-3. View

12.

Hurvitz S, Hegg R, Chung W, Im S, Jacot W, Ganju V . Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2022; 401(10371):105-117. DOI: 10.1016/S0140-6736(22)02420-5. View

13.

Dieci M, Miglietta F, Griguolo G, Guarneri V . Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. Cancer Treat Rev. 2020; 88:102064. DOI: 10.1016/j.ctrv.2020.102064. View

14.

Freedman R, Heiling H, Li T, Trapani D, Tayob N, Smith K . Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022. Ann Oncol. 2024; 35(11):993-1002. DOI: 10.1016/j.annonc.2024.07.245. View

15.

Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y . Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023; 29(8):2110-2120. PMC: 10427426. DOI: 10.1038/s41591-023-02478-2. View

16.

Xu B, Wang S, Yan M, Sohn J, Li W, Tang J . Sacituzumab govitecan in HRHER2 metastatic breast cancer: the randomized phase 3 EVER-132-002 trial. Nat Med. 2024; 30(12):3709-3716. PMC: 11645259. DOI: 10.1038/s41591-024-03269-z. View

17.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

18.

Perez E, Barrios C, Eiermann W, Toi M, Im Y, Conte P . Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE. Cancer. 2019; 125(22):3974-3984. DOI: 10.1002/cncr.32392. View

19.

Cherifi F, Da Silva A, Johnson A, Blanc-Fournier C, Abramovici O, Broyelle A . HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer. BMC Cancer. 2022; 22(1):1081. PMC: 9585737. DOI: 10.1186/s12885-022-10163-9. View

20.

Khoury K, Meisel J, Yau C, Rugo H, Nanda R, Davidian M . Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024; 30(12):3728-3736. DOI: 10.1038/s41591-024-03266-2. View